Alkermes Launches Phase 2 Trial for MDD Drug ALKS 7290
1 report, 1 independent
Updated Sat 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alkermes began a Phase 2 study evaluating ALKS 7290, an oral orexin-2 agonist, as an adjunctive therapy for major depressive disorder (MDD). The randomized, double-blind, and placebo-controlled trial will assess safety and tolerability over six weeks. The secondary goal is to determine if participants receiving ALKS 7290 plus antidepressant therapy show greater improvement in MDD symptoms than those receiving placebo plus antidepressant therapy.
From psychiatrictimes.com
Why it matters
The initiation of this proof-of-concept study for ALKS 7290 is a key step in the drug's clinical progression. Successful trial results could influence the future commercial viability and valuation of Alkermes.
From psychiatrictimes.com
Who's involved
- AlkermesThe company initiating the Phase 2 trial of ALKS 7290.
Keep exploring
The entities involved
-
Alkermes
company
Nothing else this week.